# Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects

> **NCT07024212** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Zhejiang Doer Biologics Co., Ltd.** · enrollment: 110 (estimated)

## Conditions studied

- MASLD

## Interventions

- **DRUG:** DR10624 Injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07024212
- **Lead sponsor:** Zhejiang Doer Biologics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-04-22
- **Primary completion:** 2026-05-30
- **Final completion:** 2026-08-30
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07024212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07024212, "Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07024212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*